MBX Biosciences, Inc. (MBX) earnings date
Mar 15, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 39 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | after close | 40 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | during market hours | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 12, 2026 | before open | 71 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | before open | 42 | 8-K |
| Q4 FY2024 | Mon, Mar 17, 2025 | before open | 76 | 8-K |
What they guided beta
| Q3 FY2026 | "Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing, accepted for presentation at ObesityWeek 2026 $481.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind., and BURLINGTON, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the third quarter end" exhibit |
| Q3 FY2026 | "12-week MAD (Part C) data for MBX 4291 on track for Q4 2026: Following initial Phase 1 data supporting the potential for once-monthly dosing, MBX remains on track to report unblinded data from the first cohort of the 12-week multiple ascending dose (MAD, Part C, Cohort 1) portion of its ongoing Phase 1 trial of MBX 4291." exhibit |
| Q3 FY2026 | "Preclinical data for MBX 6180 accepted for presentation at ObesityWeek 2026: MBX expects to present preclinical pharmacokinetic data for MBX 6180, its GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, in a poster presentation at ObesityWeek 2026, taking place November 14–17, 2026, in Washington, D.C." exhibit |
| Q3 FY2026 | "Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029." exhibit |
| Q3 FY2026 | "Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, " exhibit |
| Q2 FY2026 | "Nomination of development candidate MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, further expands obesity portfolio $418.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind., and BURLINGTON, Mass., Aug. 6, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the second quarter ended " exhibit |
| Q2 FY2026 | "Phase 3 trial of once-weekly canvuparatide now recruiting: MBX remains on track to initiate a Phase 3 pivotal trial of once-weekly canvuparatide in chronic hypoparathyroidism in Q3 2026." exhibit |
| Q2 FY2026 | "The Company remains on track to report data from the first cohort of the 12-week MAD (Part C) in Q4 2026." exhibit |
| Q2 FY2026 | "The Company expects to present preclinical data from MBX 6180 at a scientific meeting in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MBX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MBX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MBX/"><img src="https://veritasdata.dev/embed/MBX.svg" alt="MBX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MBX/)
Script
<script async src="https://veritasdata.dev/embed/MBX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MBX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.